RCTY yields 2000000.00% · ABBV yields 3.06%● Live data
📍 RCTY pulled ahead of the other in Year 1
Combined, RCTY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RCTY + ABBV for your $10,000?
Rocket City Enterprises, Inc., through its subsidiaries, operates as a solution provider in the automotive sector in the United States. Its subsidiaries include J. Dobisch Consultants, Inc., Complete Auto Management, LLC, GIGcom, Inc., J. Dobisch Consultants, Inc., doing business as, Complete Auto, operates as an online solution provider that offers proprietary software, personnel, and design solutions to various automotive dealerships. Complete Auto Management, LLC, doing business as, IT Lagoon, provides online solutions featuring a range of software development services from simple Web design to complex systems. These services include Web site design, Web development, ecommerce, shopping cart, and Web enabled applications. GIGcom, Inc., a Web design and application development firm, provides a portfolio of products and services for small to medium sized businesses. These products and services include domain registration, Web site hosting, Web site design, email accounts, search engine optimization, sponsored ad management, e-commerce solutions, and e-learning applications. The company was formerly known as Rocket City Automotive Group, Inc. and changed its name to Rocket City Enterprises, Inc. in August 2007. The company was incorporated in 1997 and is based in Orlando, Florida.
Full RCTY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.